180 related articles for article (PubMed ID: 19016745)
1. Role of the RUNX1-EVI1 fusion gene in leukemogenesis.
Maki K; Yamagata T; Mitani K
Cancer Sci; 2008 Oct; 99(10):1878-83. PubMed ID: 19016745
[TBL] [Abstract][Full Text] [Related]
2. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
Tokita K; Maki K; Mitani K
Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
[TBL] [Abstract][Full Text] [Related]
3. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
4. Acute promyelocytic leukemia relapsing as secondary acute myelogenous leukemia with translocation t(3;21)(q26;q22) and RUNX1-MDS1-EVI1 fusion transcript.
Park TS; Choi JR; Yoon SH; Song J; Kim J; Kim SJ; Kwon O; Min YH
Cancer Genet Cytogenet; 2008 Dec; 187(2):61-73. PubMed ID: 19027486
[TBL] [Abstract][Full Text] [Related]
5. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
6. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
[TBL] [Abstract][Full Text] [Related]
7. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
[TBL] [Abstract][Full Text] [Related]
8. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract][Full Text] [Related]
9. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
10. A 5' untranslated region containing the IRES element in the Runx1 gene is required for angiogenesis, hematopoiesis and leukemogenesis in a knock-in mouse model.
Nagamachi A; Htun PW; Ma F; Miyazaki K; Yamasaki N; Kanno M; Inaba T; Honda Z; Okuda T; Oda H; Tsuji K; Honda H
Dev Biol; 2010 Sep; 345(2):226-36. PubMed ID: 20647008
[TBL] [Abstract][Full Text] [Related]
11. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
12. RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
Nakamura Y; Ichikawa M; Oda H; Yamazaki I; Sasaki K; Mitani K
Leuk Res; 2018 Nov; 74():14-20. PubMed ID: 30278283
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
[TBL] [Abstract][Full Text] [Related]
14. The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.
Senyuk V; Chakraborty S; Mikhail FM; Zhao R; Chi Y; Nucifora G
Oncogene; 2002 May; 21(20):3232-40. PubMed ID: 12082639
[TBL] [Abstract][Full Text] [Related]
15. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
16. Core binding factor genes and human leukemia.
Hart SM; Foroni L
Haematologica; 2002 Dec; 87(12):1307-23. PubMed ID: 12495904
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Sasaki K; Yamagata T; Mitani K
Cancer Sci; 2008 Feb; 99(2):414-22. PubMed ID: 18271940
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
[TBL] [Abstract][Full Text] [Related]
19. [Detection of t(3 ; 21) (q26 ; q22) with AML1/EVI1 mRNA during progression of myelodysplastic syndrome to acute myeloid leukemia].
Choi I; Goto T; Nagano M; Muta K; Yufu Y; Uike N; Kozuru M; Abe Y; Nisimura J
Rinsho Ketsueki; 1999 Jun; 40(6):518-20. PubMed ID: 10422292
[TBL] [Abstract][Full Text] [Related]
20. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]